These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35396730)

  • 21. Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic review and meta-analysis.
    De A; Roy A; Verma N; Mishra S; Premkumar M; Taneja S; Singh V; Duseja A
    Nephrology (Carlton); 2022 Jan; 27(1):82-89. PubMed ID: 34453374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China.
    Hu C; Yuan G; Liu J; Huang H; Ren Y; Li Y; Chen X; Li W; Wu T; Deng H; Peng Y; Zhang YY; Zhou Y
    Can J Gastroenterol Hepatol; 2018; 2018():3908767. PubMed ID: 30538973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
    Wilson E; Covert E; Hoffmann J; Comstock E; Emmanuel B; Tang L; Husson J; Chua J; Price A; Mathur P; Rosenthal E; Kattakuzhy S; Masur H; Kottilil S
    J Hepatol; 2019 Sep; 71(3):498-504. PubMed ID: 31173815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
    Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
    J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
    Hezode C; Reau N; Svarovskaia ES; Doehle BP; Shanmugam R; Dvory-Sobol H; Hedskog C; McNally J; Osinusi A; Brainard DM; Miller MD; Mo H; Roberts SK; O'Leary JG; Shafran SD; Zeuzem S
    J Hepatol; 2018 May; 68(5):895-903. PubMed ID: 29221887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
    Papaluca T; Roberts SK; Strasser SI; Stuart KA; Farrell G; MacQuillan G; Dore GJ; Wade AJ; George J; Hazeldine S; O'Beirne J; Wigg A; Fisher L; McGarity B; Sawhney R; Sinclair M; Thomas J; Valiozis I; Weltman M; Wilson M; Woodward A; Ahlenstiel G; Haque M; Levy M; Prewett E; Sievert W; Sood S; Tse E; Valaydon Z; Bowden S; Douglas M; New K; O'Keefe J; Hellard M; Doyle J; Stoove M; Thompson AJ
    Clin Infect Dis; 2021 Nov; 73(9):e3288-e3295. PubMed ID: 32887983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study.
    Tapper EB; Bacon BR; Curry MP; Dieterich DT; Flamm SL; Guest LE; Kowdley KV; Lee Y; Tsai NC; Younossi ZM; Afdhal NH
    Hepatology; 2016 Dec; 64(6):1893-1899. PubMed ID: 27533287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.
    Younossi ZM; Stepanova M; Jacobson IM; Asselah T; Gane EJ; Lawitz E; Foster GR; Roberts SK; Thompson AJ; Willems BE; Welzel TM; Pearlman B; Younossi I; Racila A; Henry L
    Aliment Pharmacol Ther; 2018 Jan; 47(2):259-267. PubMed ID: 29181842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
    Smith DA; Bradshaw D; Mbisa JL; Manso CF; Bibby DF; Singer JB; Thomson EC; da Silva Filipe A; Aranday-Cortes E; Ansari MA; Brown A; Hudson E; Benselin J; Healy B; Troke P; McLauchlan J; Barnes E; Irving WL
    J Viral Hepat; 2021 Sep; 28(9):1256-1264. PubMed ID: 34003556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
    Da BL; Lourdusamy V; Kushner T; Dieterich D; Saberi B
    Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):859-861. PubMed ID: 32541241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan.
    Huang YT; Hsieh YY; Chen WM; Tung SY; Wei KL; Shen CH; Chang KC; Lu CK; Yen CW; Lu SN; Hung CH; Chang TS
    BMC Gastroenterol; 2021 Jun; 21(1):259. PubMed ID: 34118889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A real-world study of the efficacy and safety of sofosbuvir and velpatasvir in the treatment of HCV-infected patients in a county in northern China].
    Qiu LX; Yu HB; Lin W; Liu YR; Qiu YD; Hu ZJ; Pang XH; Zhang J; Liu YL
    Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):395-401. PubMed ID: 35545564
    [No Abstract]   [Full Text] [Related]  

  • 35. Sofosbuvir-velpatasvir in Mexican patients with hepatitis C: A retrospective review.
    Pérez-Hernández JL; Arce-Salinas CA; Lehmann-Mendoza R; Torre-Delgadillo A; Castro-Narro GE; Cerda-Reyes E; Ramos-Gómez MV; Juárez-Chavez L; Dehesa-Violante M; Muñoz-Espinoza LE; Cisneros-Garza LE; Aiza-Haddad I; Velarde-Ruiz-Velasco JA; Contreras-Omaña R; García-Casarreal N; Carmona-Castañeda A; Higuera-De la Tijera F
    Rev Gastroenterol Mex (Engl Ed); 2022; 87(1):52-58. PubMed ID: 34774460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
    Mangia A; Milligan S; Khalili M; Fagiuoli S; Shafran SD; Carrat F; Ouzan D; Papatheodoridis G; Ramji A; Borgia SM; Wedemeyer H; Losappio R; Pérez-Hernandez F; Wick N; Brown RS; Lampertico P; Doucette K; Ntalla I; Ramroth H; Mertens M; Vanstraelen K; Turnes J
    Liver Int; 2020 Aug; 40(8):1841-1852. PubMed ID: 32449966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China.
    Yun H; Zhao G; Sun X; Shi L
    BMJ Open; 2020 Aug; 10(8):e035224. PubMed ID: 32819983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
    Liu CH; Chen CY; Su WW; Tseng KC; Lo CC; Liu CJ; Chen JJ; Peng CY; Shih YL; Yang SS; Huang CS; Huang KJ; Chang CY; Tsai MC; Kao WY; Fang YJ; Chen PY; Su PY; Tseng CW; Huang JJ; Lee PL; Lai HC; Hsieh TY; Chang CH; Huang YJ; Lee FJ; Chang CC; Kao JH
    Gut; 2022 Jan; 71(1):176-184. PubMed ID: 33408122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.
    von Felden J; Vermehren J; Ingiliz P; Mauss S; Lutz T; Simon KG; Busch HW; Baumgarten A; Schewe K; Hueppe D; Boesecke C; Rockstroh JK; Daeumer M; Luebke N; Timm J; Schulze Zur Wiesch J; Sarrazin C; Christensen S
    Aliment Pharmacol Ther; 2018 May; 47(9):1288-1295. PubMed ID: 29536554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir.
    Wu CK; Chen LW; Chang TS; Tung SY; Lin CY; Hung CH; Lu SN; Lin CL; Chen CH; Hsu CW; Hu TH; Sheen IS
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215955
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.